Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Adenocarcinoma of Lung 23Non-Squamous Non-Small Cell Lung Cancer 21Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 15Brain Neoplasms 14Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 5Respiratory Tract Diseases 5Carcinoma 5Breast Neoplasms 5Adenocarcinoma 5Thoracic Neoplasms 4Recurrence 4Pancreatic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Colonic Neoplasms 4Salivary Gland Neoplasms 3Respiratory Tract Neoplasms 3Rectal Neoplasms 3Lung Diseases 3Esthesioneuroblastoma, Olfactory 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Thymoma 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Erlotinib Hydrochloride × Thoracic × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡